NICE Multiple Technology Appraisal (MTA)

The following NICE appraisal, published 14 July 2021, has been endorsed by Healthcare Improvement Scotland: NICE (Multiple) Technology Appraisal Guidance No 715 – Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed.

This NICE Multiple Technology Appraisal (MTA) partially updates NICE MTA 375, and provides guidance on adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis. Healthcare Improvement Scotland has advised that the recommendations are as valid for Scotland as for England and Wales. Further information is available here.